Report is Available for Download at: www.lifesciadvisors.com/clients/innate
Previously, we discussed the IPH21 Phase 1 data that was reported by Innate Pharma and concluded that it justified further clinical studies. Innate’s development partner, Bristol-Myers Squibb (NYSE: BMY; “BMS”), just announced the company’s first clinical trial with IPH21, which will be in combination with an anti-PD1 antibody in patients with five different forms of advanced solid tumors.
Safety and Efficacy to be Measured of IPH21/Anti-PD1 Combo in Phase 1 BMS Study. The aim of the Phase 1 study that was just announced by BMS is to determine the safety and clinical activity of the IPH21/BMS-936558 combination treatment. BMS-936558 is a fully-human antibody that targets the inhibitory receptor expressed on activated T-cells called PD-1 or programmed death-1. Thus the primary outcome will be safety with the secondary outcomes including a preliminary assessment of efficacy that will be measured by tumor assessment.
